The Europa Pavilion in Paris was bustling with over 16,000 dermatologists, researchers, and representatives from global pharmaceutical companies at the 34th European Academy of Dermatology and Venereology (EADV). This gathering provided a comprehensive snapshot of trends in the global dermatological treatment market. Notably, the booth of South Korean company Celltrion drew significant attention, standing out as the only major biosimilar firm with a standalone presence.
At the heart of the expansive exhibition hall, a structure adorned with the Celltrion logo gleamed under the lights. Attendees eagerly lined up to collect informational pamphlets from the booth. As the exhibition doors opened, the narrow walkways quickly filled to capacity with a surge of visitors.
On the first day’s poster session, Celltrion’s booth wall—featuring a large e-poster—was quickly surrounded by intrigued spectators. The display presented Phase 1 clinical trial results for the secukinumab biosimilar “CT-P55” through clear tables and graphs. At one point, an observer was overheard explaining to a colleague, “The AUC and Cmax are virtually identical,” as they examined the overlapping pharmacokinetic curves.
CT-P55 underwent a 1:1:1 randomized comparison with the original secukinumab (EU and US approved versions) in healthy adult males. Following a single 150 mg subcutaneous injection, the 22-week follow-up analysis demonstrated equivalence in three critical areas: drug exposure (AUC, Cmax), safety, and immunogenicity. A Celltrion spokesperson highlighted, “We’ve established initial equivalence signals in PK, safety, and immunogenicity. This paves the way for our Phase 3 trial involving 375 patients with moderate to severe plaque psoriasis.”
Attendees at the poster display were seen photographing parts of the presentation with their phones and taking notes, indicating high interest. Badges from big pharma researchers were also prominently visible nearby.
On the 18th, the venue for Celltrion’s symposium was buzzing an hour before the presentations began. Attendees with translation devices gathered in small groups, engaging in lively discussions. The stage screen prominently displayed the topic: “Understanding and Utilizing Biosimilars in Chronic Spontaneous Urticaria.”
Professor Martin Metz from Germany’s Charité University, who chaired the session, opened by stating, “Biosimilars have moved beyond initial skepticism and are now reshaping treatment paradigms.” Professor Fernando de Mora from Barcelona Autonomous University followed, emphasizing, “The key lies in clinical equivalence, not structural similarity.” Professor Peter from Guy’s and St Thomas’ Hospital in the UK added, “Switching for IBD patients has proven safe, and the cost savings have enabled new treatment approaches.”
The audience remained attentive throughout, nodding in agreement. The subsequent Q&A session sparked discussions on practical clinical applications and patient education strategies. An Asian-European dermatologist in attendance was particularly engaged, frequently capturing photos and showing great interest in the safety profiles and cost-effectiveness of biosimilars.
In an on-site interview, Celltrion’s European head, Hah Tae-hoon, stated, “The launch of Omilclo expands our antibody biosimilar portfolio in dermatology and strengthens our global market position. At EADV 2025, we are the only major biosimilar company with a standalone booth, reinforcing Celltrion’s brand and fostering direct engagement with healthcare professionals.”
He added, “As Omilclo enters the global market as a first mover, it will broaden treatment access for patients. We are committed to leveraging Celltrion’s R&D capabilities and direct sales infrastructure to increase our market share.”
As Hah noted, this year’s EADV transcended mere academic exchange, serving as a platform to gauge the future of the global dermatological treatment landscape. The crowds at Celltrion’s booth and the energy of the symposium underscored that biosimilars have evolved from mere alternatives to become global game-changers. At this event, Celltrion clearly marked its new starting point in the European dermatology market.
